Differential expression of CCN1/CYR61, CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in neurofibromatosis type 1 tumorigenesis

Journal of Neuropathology and Experimental Neurology

Volumn 69, Issue 1, 2010, Pages 60-69

  Pasmant, Eric ^a   Ortonne, Nicolas ^a   Rittié, Laure ^a   Laurendeau, Ingrid ^a   Lévy, Pascale ^a   Lazar, Vladimir ^a   Parfait, Béatrice ^a   Leroy, Karen ^a   Dessen, Philippe ^a   Valeyrie Allanore, Laurence ^a   Perbal, Bernard ^a   Wolkenstein, Pierre ^a   Vidaud, Michel ^a   Vidaud, Dominique ^a   Bièche, Ivan ^a  

^a INSERM   (France)

Author keywords

CCN genes; MPNST; Neurofibroma; Neurofibromatosis type 1; Real time RT PCR quantification

Indexed keywords

CALGRANULIN A; CALGRANULIN B; CD36 ANTIGEN; COLLAGENASE 3; CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE RICH PROTEIN 61; GELATINASE A; GELATINASE B; GROWTH FACTOR; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE 14; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; PROTEIN CCN4; PROTEIN CCN5; STROMELYSIN; STROMELYSIN 3; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ANGIOGENESIS; ARTICLE; CARCINOGENESIS; CELL ADHESION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; FIBROGENESIS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NERVE SHEATH TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL NERVE TUMOR; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ADOLESCENT; ADULT; CARCINOGENICITY TESTS; CELL DIFFERENTIATION; CELLS, CULTURED; CYSTEINE-RICH PROTEIN 61; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; NEUROFIBROMA; NEUROFIBROMATOSIS 1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; SCHWANN CELLS; SKIN NEOPLASMS; STATISTICS, NONPARAMETRIC; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 74049128988     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181c79bff     Document Type: Article

References (43)

1. Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999;89:1-6
2. Cawthon RM, Weiss R, Xu GF, et al. A major segment of the neuro-fibromatosis type 1 gene: CDNA sequence, genomic structure, and point mutations. Cell 1990;62:193-201
3. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibro-matosis gene: Identification of a large transcript disrupted in three NF1. Science 1990;249:181-186
4. DeClue JE, Papageorge AG, Fletcher JA, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992;69:265-273
5. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002;62:1573-1577
6. Zhu Y, Ghosh P, Charnay P, et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002;296:920-922
7. Scheithauer B, Woodruff J, Erlandson R. Tumors of the peripheral nervous system. In: Atlas of Tumor Pathology. Third Series. Fascicle 24. Washington, DC: Armed Forces Institute of Pathology, 1999
8. Leroy K, Dumas V, Martin-Garcia N, et al. Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: A clinicopatho-logic and molecular study of 17 patients. Arch Dermatol 2001;137: 908-913
9. Lévy P, Bièche I, Leroy K, et al. Molecular profiles of neurofibromatosis type 1Yassociated plexiform neurofibromas: Identification of a gene expression signature of poor prognosis. Clin Cancer Res 2004;10:3763-3771
10. Holtkamp N, Reuss DE, Atallah I, et al. Subclassification of nerve sheath tumors by gene expression profiling. Brain Pathol 2004;14: 258-264
11. Watson MA, Perry A, Tihan T, et al. Gene expression profiling reveals unique molecular subtypes of neurofibromatosis type IYassociated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol 2004; 14:297-303
12. Miller SJ, Rangwala F, Williams J, et al. Large-scale molecular comparison of human Schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006;66:2584-2591
13. Avellana-Adalid V, Bachelin C, Lachapelle F, et al. In vitro and in vivo behaviour of NDF-expanded monkey Schwann cells. Eur J Neurosci 1998;10:291-300
14. Glasow A, Kiess W, Anderegg U, et al. Expression of leptin (Ob) and leptin receptor (Ob-R) in human fibroblasts: Regulation of leptin secretion by insulin. J Clin Endocrinol Metab 2001;86:4472-4479
15. Smadja DM, Bièche I, Uzan G, et al. PAR-1 activation on human late endothelial progenitor cells enhances angiogenesis in vitro with up-regulation of the SDF-1/CXCR4 system. Arterioscler Thromb Vasc Biol 2005;25:2321-2327
16. Royer B, Varadaradjalou S, Saas P, et al. Autocrine regulation of cord bloodYderived human mast cell activation by IL-10. J Allergy Clin Immunol 2001;108:80-86
17. Bachelin C, Lachapelle F, Girard C, et al. Efficient myelin repair in the macaque spinal cord by autologous grafts of Schwann cells. Brain 2005; 128:540-549
18. Rosenbaum T, Rosenbaum C, Winner U, et al. Long-term culture and characterization of human neurofibroma-derived Schwann cells. J Neurosci Res 2000;61:524-532
19. Bieche I, Parfait B, Le Doussal V, et al. Identification of CGA as a novel estrogen receptorYresponsive gene in breast cancer: An outstanding candidate marker to predict the response to endocrine therapy. Cancer Res 2001;61:1652-1658
20. Bièche I, Onody P, Laurendeau I, et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999;45:1148-1156
21. Mann H, Whitney D. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 1947;18:50-60
22. Didier G, Brezellec P, Remy E, et al. GeneANOVA-gene expression analysis of variance. Bioinformatics 2002;18:490-491
23. Chevalier G, Yeger H, Martinerie C, et al. NovH: Differential expression in developing kidney and Wilm's tumors. Am J Pathol 1998;152: 1563-1575
24. Leask A, Abraham DJ. All in the CCN family: Essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006;119: 4803-4810
25. Pennica D, Swanson TA, Welsh JW, et al. WISP genes are members of the connective tissue growth factor family that are upregulated in wnt-1Ytransformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A 1998;95:14717-14722
26. Schwartz DR, Wu R, Kardia SL, et al. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 2003; 63:2913-2922
27. Bafico A, Liu G, Goldin L, et al. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 2004;6:497-506
28. Nguyen N, Kuliopulos A, Graham RA, et al. Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1Ydependent migration of breast cancer cells. Cancer Res 2006;66:2658-2665
29. Lévy P, Vidaud D, Leroy K, et al. Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. Mol Cancer 2004;3:20
30. Jeong WI, Do SH, Jeong DH, et al. Kinetics of MMP-1 and MMP-3 produced by mast cells and macrophages in liver fibrogenesis of rat. Anticancer Res 2006;26:3517-3526
31. Poola I, DeWitty RL, Marshalleck JJ, et al. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 2005;11:481-483
32. Gebhardt C, Nemeth J, Angel P, et al. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006;72:1622-1631
33. Hong Y, Ho KS, Eu KW, et al. A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: Implication for tumorigenesis. Clin Cancer Res 2007;13:1107-1114
34. Di Martino E, Wild CP, Rotimi O, et al. IGFBP-3 and IGFBP-10 (CYR61) upregulation during the development of Barrett's oesophagus and associated oesophageal adenocarcinoma: Potential biomarkers of disease risk. Biomarkers 2006;11:547-561
35. Chen Y, Du XY. Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem 2007;100:1337-1345
36. Babic AM, Kireeva ML, Kolesnikova TV, et al. CYR61, a product of a growth factorYinducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1998;95:6355-6360
37. Leu SJ, Lam SC, Lau LF. Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem 2002;277:46248-46255
38. Mo FE, Muntean AG, Chen CC, et al. CYR61 (CCN1) is essential for placental development and vascular integrity. Mol Cell Biol 2002;22: 8709-8720
39. Bleau AM, Planque N, Lazar N, et al. Antiproliferative activity of CCN3: Involvement of the C-terminal module and post-translational regulation. J Cell Biochem 2007;101:1475-1491
40. Perbal B. NOV story: The way to CCN3. Cell Commun Signal 2006;4:3
41. Chen PP, Li WJ, Wang Y, et al. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS ONE 2007;2:e534
42. Xie D, Nakachi K, Wang H, et al. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001;61:8917-8923
43. Su F, Overholtzer M, Besser D, et al. WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes Dev 2002;16:46-57